Mark Wicker was quoted in “Pharma Collaborations in the COVID-19 Era Come with Legal Risks,” an article in Bloomberg Law, regarding the collaborations surrounding the COVID-19 pandemic.  

“Traditionally, deals can take a lot more time to negotiate and the innovator company can be a lot more reluctant to share their technology,” said Mark. “In light of the COVID-19 world, there is an increased willingness to do this that didn’t necessarily exist before.”

“The more you collaborate, the more you transfer technology, the more those issues come up,” Mark said. “Those are things companies are or should be focusing on in this accelerated environment.”